Prognostic factors for acute myeloid leukemia patients with t(6;9)(p23;q34) who underwent an allogeneic hematopoietic stem cell transplant

Leukemia

Volumn 26, Issue 6, 2012, Pages 1416-1419

  Ishiyama, K ^a,b   Takami, A ^a   Kanda, Y ^c   Nakao, S ^a   Hidaka, M ^d   Maeda, T ^e   Naoe, T ^f   Taniguchi, S ^g   Kawa, K ^h   Nagamura, T ⁱ   Tabuchi, K ^j   Atsuta, Y ^k   Sakamaki, H ^l  

^a KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

^b Tokyo Metropolitan Ohtsuka Hospital   (Japan)

^c JICHI MEDICAL UNIVERSITY   (Japan)

^d NATIONAL HOSPITAL ORGANIZATION KUMAMOTO MEDICAL CENTER   (Japan)

^e OSAKA UNIVERSITY HOSPITAL   (Japan)

^f NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^g TORANOMON HOSPITAL   (Japan)

^h RESEARCH INSTITUTE FOR MATERNAL AND CHILD HEALTH   (Japan)

ⁱ UNIVERSITY OF TOKYO   (Japan)

^j KANAGAWA CHILDREN'S MEDICAL CENTER   (Japan)

^k NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^l TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; METHOTREXATE; TACROLIMUS;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER PROGNOSIS; CANCER RELAPSE; CHILD; CHROMOSOME TRANSLOCATION 6; CHROMOSOME TRANSLOCATION 9; CYTOGENETICS; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; LETTER; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; TREATMENT OUTCOME; WHOLE BODY RADIATION;

EID: 84862023182     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2011.350     Document Type: Letter

References (15)

1. van der Straaten HM, van Biezen A, Brand R, Schattenberg AV, Egeler RM, Barge RM et al. Allogeneic stem cell transplantation for patients with acute myeloid leukemia or myelodysplastic syndrome who have chromosome 5 and/or 7 abnormalities. Haematologica 2005; 90: 1339-1345. (Pubitemid 41503649)
2. Slovak ML, Kopecky KJ, Cassileth PA, Harrington DH, Theil KS, Mohamed A et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 2000; 96: 4075-4083.
3. Kurosawa S, Yamaguchi T, Miyawaki S, Uchida N, Kanamori H, Usuki K et al. A Markov decision analysis of allogeneic hematopoietic cell transplantation versus chemotherapy in patients with acute myeloid leukemia in first remission. Blood 2011; 117: 2113-2120.
4. Slovak ML, Gundacker H, Bloomfield CD, Dewald G, Appelbaum FR, Larson RA et al. A retrospective study of 69 patients with t(6;9)(p23;q34) AML emphasizes the need for a prospective, multicenter initiative for rare 'poor prognosis' myeloid malignancies. Leukemia 2006; 20: 1295-1297. (Pubitemid 43905836)
5. Ishiyama K, Takami A, Kanda Y, Nakao S, Hidaka M, Maeda T et al. Allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia with t(6;9)(p23;q34) dramatically improves the patient prognosis: a matched-pair analysis. Leukemia 2011; e-pub ahead of print 26 August 2011; doi:10.1038/leu.2011.229.
6. Scrucca L, Santucci A, Aversa F. Competing risk analysis using R: an easy guide for clinicians. Bone Marrow Transplant 2007; 40: 381-387. (Pubitemid 47202424)
7. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999; 18: 695-706. (Pubitemid 29126745)
8. Garcon L, Libura M, Delabesse E, Valensi F, Asnafi V, Berger C et al. DEK-CAN molecular monitoring of myeloid malignancies could aid therapeutic stratification. Leukemia 2005; 19: 1338-1344. (Pubitemid 41136325)
9. Frohling S, Schlenk RF, Breitruck J, Benner A, Kreitmeier S, Tobis K et al. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. Blood 2002; 100: 4372-4380. (Pubitemid 35434129)
10. Oyarzo MP, Lin P, Glassman A, Bueso-Ramos CE, Luthra R, Medeiros LJ. Acute myeloid leukemia with t(6;9)(p23;q34) is associated with dysplasia and a high frequency of flt3 gene mutations. Am J Clin Pathol 2004; 122: 348-358. (Pubitemid 39145539)
11. Thiede C, Steudel C, Mohr B, Schaich M, Schakel U, Platzbecker U et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood 2002; 99: 4326-4335. (Pubitemid 34627197)
12. Kuchenbauer F, Kern W, Schoch C, Kohlmann A, Hiddemann W, Haferlach T et al. Detailed analysis of FLT3 expression levels in acute myeloid leukemia. Haematologica 2005; 90: 1617-1625. (Pubitemid 41814985)
13. Koh Y, Park J, Ahn KS, Kim I, Bang SM, Lee JH et al. Different clinical importance of FLT3 internal tandem duplications in AML according to FAB classification: possible existence of distinct leukemogenesis involving monocyte differentiation pathway. Ann Hematol 2009; 88: 1089-1097.
14. Small D. Targeting FLT3 for the treatment of leukemia. Semin Hematol 2008; 45(3 Suppl 2): S17-S21.
15. Breitenbuecher F, Markova B, Kasper S, Carius B, Stauder T, Bohmer FD et al. A novel molecular mechanism of primary resistance to FLT3-kinase inhibitors in AML. Blood 2009; 113: 4063-4073.